短暂沉默的获得性抗菌药物耐药:药敏试验面临的新挑战
细菌获得抗菌药物耐药(AMR)机制常伴随适应度代价,在无抗生素选择压力时可出现表型沉默的耐药亚群。本综述将短暂沉默的获得性AMR(tsaAMR)定义为携带获得性耐药基因但表型处于野生型分布或低于临床折点、且遗传改变可介导表达至临床相关耐药水平的现象,并描述其分子机制、与治疗失败的关联及对常规药敏试验的挑战。
要点
- tsaAMR指获得性耐药基因表型沉默但遗传改变可使其表达至临床耐药水平。
- 遗传改变包括表达量、阅读框或耐药决定簇拷贝数的改变。
- 文献报道了革兰阳性与革兰阴性病原体中tsaAMR相关体内耐药发展及治疗失败。
核心结论
- 随着获得性AMR在细菌病原体中总体扩展,tsaAMR现象可能增多。
研究设计与样本
- 本综述界定了tsaAMR,并汇总革兰阳性与革兰阴性病原体中体内耐药发展及治疗失败的相关文献。
主要发现
- 细菌获得和表达AMR机制常伴随适应度代价,进化适应与适应度代价补偿可在无抗生素选择压力时支持沉默耐药表型亚群出现。
关键数值与推荐
- tsaAMR定义为获得性耐药基因对应的表型处于野生型分布内或低于临床敏感折点,但遗传改变可介导表达至临床相关耐药水平。
- 遗传改变涉及耐药决定簇的表达、阅读框或拷贝数的改变。
临床怎么用
- 基因型方法联合常规表型药敏试验可检测基因型与表型不一致,从而识别tsaAMR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquisition and expression of antimicrobial resistance (AMR) mechanisms in bacteria are often associated with a fitness cost. Thus, evolutionary adaptation and fitness cost compensation may support the advance of subpopulations with a silent resistance phenotype when the antibiotic selection pressure is absent. However, reports are emerging on the transient nature of silent acquired AMR, describing genetic alterations that can change the expression of these determinants to a clinically relevant level of resistance, and the association with breakthrough infections causing treatment failures. This phenomenon of transiently silent acquired AMR (tsaAMR) is likely to increase, considering the overall expansion of acquired AMR in bacterial pathogens. Moreover, the augmented use of genotypic methods in combination with conventional phenotypic antimicrobial susceptibility testing (AST) will increasingly enable the detection of genotype and phenotype discrepancy. This review defines tsaAMR as acquired antimicrobial resistance genes with a corresponding phenotype within the wild-type distribution or below the clinical breakpoint for susceptibility for which genetic alterations can mediate expression to a clinically relevant level of resistance. References to in vivo resistance development and therapeutic failures caused by selected resistant subpopulations of tsaAMR in Gram-positive and Gram-negative pathogens are given. We also describe the underlying molecular mechanisms, including alterations in the expression, reading frame or copy number of AMR determinants, and discuss the clinical relevance concerning challenges for conventional AST.
引用
- Wagner TM, Howden BP, Sundsfjord A, et al. Transiently silent acquired antimicrobial resistance: an emerging challenge in susceptibility testing. J Antimicrob Chemother. 2023. PMID: 36719135. doi:10.1093/jac/dkad024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。